Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranexa Target Population Is 10%-25% Of Angina Patients; Sampling Will Be Key

Executive Summary

CV Therapeutics' launch of its second-line angina product Ranexa (ranolazine) will include an aggressive sampling program

You may also be interested in...



CV Therapeutics Sets Sights On Imdur With Ranolazine Development

CV Therapeutics is looking at Schering-Plough's Imdur (isosorbide) as a market "benchmark" for its Phase III anti-angina agent ranolazine.

Innovex Sales Support For CVT Angina Drug Based On Percentage Formula

Quintiles' contract sales division Innovex would receive up to one-third of the first two years of sales from a chronic stable angina treatment being developed by CV Therapeutics, under a commercialization deal announced May 11.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS046839

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel